AI in Medical Devices: CDSCO vs EU MDR 2027 – India’s Path to Regulatory Leadership

How AI in Medical Devices Will Be Regulated in India: CDSCO vs EU MDR 2027

By Ankur K. Khare – Biomedical Engineer | AI Ethics & Medical Innovation

India urgently needs a comprehensive CDSCO-AI regulatory framework to secure its MedTech future and prevent the dominance of foreign EU MDR and AI Acts, especially as global rules for AI in medical devices become stricter by 2027.

The Global AI Medical Device Regulatory Storm is Coming

By August 2, 2027, every AI-powered medical device entering the European Union must comply with both the EU Medical Device Regulation (MDR) and the AI Act—with no grace period. This dual compliance framework demands rigorous risk assessment, transparency, continuous monitoring, and "human oversight" of all high-risk AI systems, creating significant legal and technical barriers.

The EU classifies medical device AI as "high-risk," subjecting it to strict conformity assessment, real-world surveillance, and tightly enforced ethical principles. Manufacturers face penalties up to €35 million or 7% of global turnover for non-compliance.

India's Current AI Medical Device Landscape: CDSCO's Evolving Framework

India's Central Drugs Standard Control Organisation (CDSCO) regulates AI-based medical devices under the Medical Device Rules 2017, using a risk-based classification system (Class A-D) inspired by International Medical Device Regulators Forum (IMDRF) standards.

Recent Progress and Gaps

What India Has Done:

• Implemented risk-based reclassification of 553 medical devices in 2025, with 221 placed in highest-risk Class D

• Launched fully automated SUGAM portal for Market Standing Certificates and licensing

• Released ICMR Ethical Guidelines for AI in Healthcare (2023)

• Joined HealthAI Global Regulatory Network as a pioneer country in September 2025

Critical Gaps:

• No published standalone AI-specific framework by CDSCO—AI devices regulated mainly as "software" under generic device rules

• Limited guidance on algorithmic transparency, bias mitigation, and post-market AI surveillance

• Absence of AI-specific safety protocols for continuous learning systems

The Strategic Risk: Regulatory Import vs Indigenous Innovation

Without targeted AI policies, India risks "regulatory import"—where EU MDR/AI compliance becomes the de facto standard, potentially sidelining Indian innovation and industry priorities.

Why This Matters Now

Economic Impact: India's AI healthcare market is forecasted to reach $1.6 billion by 2025, growing at 40.6% annually. The government allocated over $1 billion for AI-driven digital health services in the 2025 budget.

Global Competition: As the EU enforces the world's strictest AI medical device regulations by 2027, Indian manufacturers may struggle to prove compliance without clear domestic standards.

Patient Safety: The lack of AI-specific safety, data governance, and post-market review requirements can jeopardize patient trust and clinical outcomes.

CDSCO vs EU MDR 2027: The Regulatory Gap

Aspect	CDSCO (India, 2025)	EU MDR + AI Act (2027)
AI-Specific Guidelines	Not yet published	Fully operational, risk-based
Risk Classification	A, B, C, D (IMDRF-aligned	High-risk AI systems (mandatory)
Post-Market Surveillance	Generic device monitoring	Mandatory real-world data, audits
Transparency & Ethics	General device obligations	Stringent AI ethics + explainability
Algorithm Oversight	Limited guidance	Human oversight mandatory
Data Governance	Basic requirements	Comprehensive dataset validation

Blueprint for India's CDSCO-AI Leadership Framework

Immediate Actions (2025-2026)

1. Develop CDSCO-AI Guidelines

• Create AI-specific risk classification beyond generic SaMD categories

• Establish algorithmic transparency and explainability requirements

• Define continuous learning and model update protocols

2. Strengthen Infrastructure

• Expand SUGAM portal for AI-specific submissions and monitoring

• Create centralized adverse event database for AI medical devices

• Establish AI competency centers within CDSCO

3. Ethical Framework Integration

• Build upon ICMR's 2023 AI ethics guidelines for practical implementation

• Address algorithmic bias, fairness, and cultural context considerations

• Ensure data sovereignty and protection aligned with India's Digital Personal Data Protection Act

Medium-term Strategy (2026-2027)

4. Regulatory Sandboxes

• Launch fast-track approval pilots for domestic AI innovations

• Create controlled testing environments for breakthrough AI technologies

• Establish partnerships with IITs, AIIMS, and industry for validation

5. Global Harmonization

• Align with—but not simply mirror—best practices from EU MDR/AI Act

• Leverage India's position in HealthAI Global Regulatory Network

• Establish mutual recognition agreements with key markets

The National Thought Leadership Opportunity

India stands at a historic crossroads. With over 1.4 billion people and mounting healthcare challenges, AI represents a transformative opportunity to leapfrog traditional healthcare limitations.

Strategic Advantages:

• Digital Infrastructure: National Digital Health Mission creating unified health IDs and data systems

• Innovation Ecosystem: Growing AI startup sector and government support through IndiaAI strategy

• Global Position: Pioneer member of HealthAI Global Regulatory Network

The Clock is Ticking: By 2027, European regulations will set the global standard. India must act decisively to establish its own CDSCO-AI framework by 2026, creating bespoke standards that reflect Indian healthcare needs while maintaining global competitiveness.

Call to Action: India's MedTech Sovereignty

For Policymakers: Launch an immediate CDSCO-AI rulemaking agenda, establishing India as a thought leader in ethical AI healthcare regulation.

For Industry: Engage proactively with CDSCO to shape indigenous standards that promote innovation while ensuring patient safety.

For Healthcare Professionals: Participate in AI governance discussions to ensure clinical realities inform regulatory frameworks.

India's MedTech future hangs in the balance. The choice is clear: lead with indigenous AI healthcare standards or follow European frameworks that may not suit Indian contexts.

The time for action is now. Let's write our own rules before someone else does.